Clinical trial results:
A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy

Summary

EudraCT number	2016-004200-65
Trial protocol	ES FR
Global end of trial date	10 October 2019

Results information

Result version number	v1 (current)
This version publication date	01 October 2020
First version publication date	01 October 2020

Trial information

Trial identification

Sponsor protocol code	LP0162-1325

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	LEO Pharma A/S
Sponsor organisation address	Industriparken 55, Ballerup, Denmark, 2750
Public contact	Clinical disclosure specialist, LEO Pharma A/S, +45 44945888, disclosure@leo-pharma.com
Scientific contact	disclosure@leo-pharma.com, LEO Pharma A/S, +45 44945888, disclosure@leo-pharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 February 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	10 October 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of tralokinumab compared with placebo in treating moderate-to-severe Atopic dermatitis.

Protection of trial subjects:

This clinical trial was conducted to conform to the principles of the Declaration of Helsinki as adopted by the 18th World Medical Association General Assembly, 1964, and subsequent amendments.
All subjects received written and verbal information concerning the clinical trial. Subjects were asked to consent that their personal data were recorded, collected, processed and could
be transferred to EU and non-EU countries in accordance with any national legislation regulating privacy and data protection.
Both during the initial treatment period and the maintenance treatment period, some subjects were randomised to placebo treatment. If medically necessary (i.e. to control intolerable atopic dermatitis [AD] symptoms), rescue treatment for AD could be provided to subjects throughout the trial, both during the initial treatment period and the maintenance treatment period, at the discretion of the investigator.
For the first 3 investigational medicinal product (IMP) dosing visits in both the initial treatment period (i.e. Weeks 0, 2, and 4) and in open-label treatment, subjects were monitored after IMP administration for immediate drug reactions for a minimum of 2 hours with vital signs taken every 30 minutes or until stable, whichever was later. Vital signs were documented in the electronic case report forms.
Appropriate drugs, such as epinephrine, antihistamines, corticosteroids, etc., and medical equipment to treat acute anaphylactic reactions were immediately available at trial sites, and trial personnel was trained to recognise and respond to anaphylaxis according to local guidelines.

Background therapy:

All subjects were to use an emollient twice daily (or more, as needed) for at least 14 days before randomisation and were to continue this treatment throughout the trial.

Evidence for comparator: -

Actual start date of recruitment	31 March 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 96
Country: Number of subjects enrolled	France: 108
Country: Number of subjects enrolled	Germany: 273
Country: Number of subjects enrolled	United States: 198
Country: Number of subjects enrolled	Japan: 127

Worldwide total number of subjects	802
EEA total number of subjects	477

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	759
From 65 to 84 years	42
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

Trial start date: May 30, 2017
Primary completion date: August 7, 2018
Trial completion date: October 14, 2019

The trial was conducted in 5 countries: Germany, France, Spain, the United States, and Japan.

Pre-assignment

Screening details:

The screening period was 2 to 6 weeks and included 1 or 2 visits. The exact duration depended on the wash-out period defined by the exclusion criteria. If no wash-out or only a 2-week wash-out was required, screening Visits 1 and 2 were combined. Eligibility was assessed at the (first) screening visit and on Day 0 prior to randomisation.

Period 1

Period 1 title	Initial treatment period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

This was a double-blind trial in which tralokinumab and placebo were visually distinct from each other. The IMP was handled and administered by a qualified, unblinded healthcare professional (HCP) at the site who was not involved in the management of trial subjects and who did not perform any of the assessments.

Arms

Are arms mutually exclusive?	Yes
Arm title	Initial treatment period - Tralokinumab 300 mg Q2W

Arm description:

Week 0 to Week 16:

Tralokinumab 300 mg Q2W

Tralokinumab: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for SC administration.

Arm type	Experimental
Investigational medicinal product name	Tralokinumb 300 mg Q2W
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab. IMP was administered by a qualified, unblinded HCP. The injections were administered into the SC tissue of the upper arm, anterior thigh, or abdomen, separated by at least 3 cm.

Arm title	Initial treatment period - Placebo Q2W

Arm description:

Week 0 to Week 16:

Placebo Q2W

Placebo: Placebo contains the same excipients, in the same concentration, only lacking tralokinumab.

Arm type	Placebo
Investigational medicinal product name	Placebo Q2W
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Dosage and administration details:

At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo IMP was administered by a qualified, unblinded HCP. The injections were administered into the SC tissue of the upper arm, anterior thigh, or abdomen, separated by at least 3 cm.

Number of subjects in period 1	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W
Started	603	199
Completed	550	179
Not completed	53	20
Discontinued IMP before Week 16	51	18
Not dosed	2	2

Period 2

Period 2 title	Open-label treatment
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Open-label Treatment: Tralokinumab 300 mg Q2W + optional TCS

Arm description:

Week 16 to Week 52:

Subjects receiving initial treatment with tralokinumab/placebo Q2W who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) OR Subjects receiving maintenance treatment with tralokinumab 300 mg Q2W/Q4W or placebo Q2W assigned to open-label treatment after Week 16 with tralokinumab 300 mg Q2W regimen + optional TCS if: -IGA of at least 2 and not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA=0 at Week 16; OR -IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e. over 3 consecutive visits) for subjects with IGA=1 at Week 16; OR -Not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA>1 at Week 16.

Arm type	Experimental

Investigational medicinal product name	Open-label Tralokinumab 300 mg Q2W + Optional TCS
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg. IMP was administered by a qualified HCP. Subjects had the option to self-administer
tralokinumab – or have tralokinumab administered by a caregiver – in their home after adequate training by site staff at the investigator's discretion. The injections were administered into the SC tissue of the upper
arm, anterior thigh, or abdomen, separated by at least 3 cm.

Number of subjects in period
2

Investigational medicinal product name	Maintenance Tralokinumab 300 mg Q2W
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab. IMP was administered by a qualified, unblinded HCP. IMP was administered by a qualified, unblinded HCP. The injections were administered into the SC tissue of the upper arm, anterior thigh, or abdomen, separated by at least 3 cm.

Arm title	Maintenance Treatment Period - Tralokinumab 300 mg Q4W

Arm description:

Week 16 to Week 52: Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to tralokinumab 300 mg Q4W maintenance dosing regimen.

Arm type	Experimental
Investigational medicinal product name	Maintenance Tralokinumab 300 mg Q4W
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo. IMP was administered by a qualified, unblinded HCP. The injections were administered into the SC tissue of the upper arm, anterior thigh, or abdomen, separated by at least 3 cm.

Arm title	Maintenance Treatment Period - Placebo Q2W

Arm description:

Week 16 to Week 52: Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to placebo Q2W dosing regimen.

Arm type	Placebo
Investigational medicinal product name	Maintenance Placebo Q2W
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo. IMP was administered by a qualified, unblinded HCP. The injections were administered into the SC tissue of the upper arm, anterior thigh, or abdomen, separated by at least 3 cm.

Arm title	Maintenance Treatment Period -Placebo Q2W - Tralokinumab Naive

Arm description:

Week 16 to Week 52: Subjects achieving a clinical response at Week 16 and initially randomised to placebo re-assigned to placebo Q2W.

Arm type	Placebo
Investigational medicinal product name	Maintenance Placebo Q2W - Tralokinumab Naive
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo. IMP was administered by a qualified, unblinded HCP. The injections were administered into the SC tissue of the upper arm, anterior thigh, or abdomen, separated by at least 3 cm.

Number of subjects in period 3[2]	Maintenance Treatment Period - Tralokinumab 300 mg Q2W	Maintenance Treatment Period - Tralokinumab 300 mg Q4W	Maintenance Treatment Period - Placebo Q2W
Started	71	78	36
Completed	44	53	21
Not completed	27	25	15
Discontinued IMP	4	6	4
Completed Week 50	-	-	1
Transfer to open-label treatment	21	18	9
Not dosed - transfer to open-label	2	1	1

Number of subjects in period 3[2]	Maintenance Treatment Period - Placebo Q2W - Tralokinumab Naive
Started	29
Completed	15
Not completed	14
Discontinued IMP	4
Completed Week 50	-
Transfer to open-label treatment	10
Not dosed - transfer to open-label	-

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: The maintenance treatment period was in parallel to the open-label treatment period. Subjects from the initial treatment phase entered either into
the maintenance treatment period or the open-label treatment period.

Period 4

Period 4 title	Open-label (Short-term extension)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Open-label Treatment - Tralokinumab 300 mg Q2W + Optional TCS

Arm description:

Week 52 to Week 66 [Short term extension (Japan only)]:

Japanese subjects who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy.

Each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.

Arm type	Experimental

Investigational medicinal product name	Open-label Tralokinumab 300 mg Q2W + Optional TCS
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg. IMP was administered by a qualified HCP. Subjects had the option to self-administer tralokinumab – or have tralokinumab administered by a caregiver – in their home after adequate training by site staff at the investigator's discretion. The injections were administered into the SC tissue of the upper arm, anterior thigh, or abdomen, separated by at least 3 cm.

Number of subjects in period 4[3]	Open-label Treatment - Tralokinumab 300 mg Q2W + Optional TCS
Started	65
Completed	62
Not completed	3
Discontinued IMP	3

Notes:

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: The open-label treatment period was in parallel to the maintenance treatment period. Subjects from the initial treatment period entered either into the open-label treatment period or maintenance treatment period. This period was relevant only for selected Japanese subjects transferring to open-label treatment after Week 16, so they could receive 52 weeks of active treatment.

Baseline characteristics

Reporting groups	
Reporting group title	Initial treatment period - Tralokinumab 300 mg Q2W
Reporting group description: Week 0 to Week 16: Tralokinumab 300 mg Q2W Tralokinumab: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for SC administration.	
Reporting group title	Initial treatment period - Placebo Q2W
Reporting group description: Week 0 to Week 16: Placebo Q2W Placebo: Placebo contains the same excipients, in the same concentration, only lacking tralokinumab.	

Reporting group values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W	Total
Number of subjects	603	199	802
Age categorical Units: Subjects			
Adults (18-64 years)	574	185	759
From 65-84 years	28	14	42
85 years and over	1	0	1
Age continuous Units: years			
arithmetic mean	38.6	39.4	
standard deviation	± 13.7	± 15.2	-
Gender categorical Units: Subjects			
Female	252	76	328
Male	351	123	474
Race/Ethnicity Units: Subjects			
White	426	138	564
Black or african american	41	18	59
Asian	120	40	160
American indian or alaska native	1	0	1
Native hawaiian or other pacific islander	5	0	5
Other	8	0	8
Missing	2	3	5
Investigator's Global Assessment			
Measure description: The Investigator's Global Assessment (IGA) is an instrument used in clinical trials to rate the severity of the subject's global atopic dermatitis and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).			
Units: Subjects			

Clear	0	0	0
Almost clear	0	0	0
Mild	0	0	0
Moderate	296	95	391
Severe	305	102	407
Missing	2	2	4
Eczema Area and Severity Index			
Measure description: The Eczema Area and Severity Index (EASI) is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition. Measure Analysis Population Description: Number of subjects analysed = subjects with available data for the baseline parameter.			
Units: Units on a scale			
arithmetic mean	32.2	32.9	
standard deviation	± 13.7	± 13.9	-
Scoring Atopic Dermatitis			
The Scoring Atopic Dermatitis (SCORAD) is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease. Measure Analysis Population Description: Number of subjects analysed = subjects with available data for the baseline parameter.			
Units: Units on a scale			
arithmetic mean	70.3	71.7	
standard deviation	± 13.0	± 12.5	-
Dermatology Life Quality Index			
The Dermatology Life Quality Index (DLQI) consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their health-related quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4-point Likert scale (0='not at all/not relevant'; 1='a little'; 2='a lot'; 3='very much'). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor health-related quality of life.			
Units: Units on a scale			
arithmetic mean	16.8	17.0	
standard deviation	± 7.1	± 6.6	-
Worst Daily Pruritus Numeric rating scale (weekly average)			
Measure description: Subjects assess their worst itch severity over the past 24 hours using an 11-point NRS (Numeric rating scale; 'Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'. Measure Analysis Population Description: Number of subjects analysed = subjects with available data for the baseline parameter			
Units: Units on a scale			
arithmetic mean	7.7	7.7	
standard deviation	± 1.4	± 1.4	-
Body surface area affected by AD			
Measure Analysis Population Description: Number of subjects analysed = subjects with available data for the baseline parameter.			
Units: percentage affected			
arithmetic mean	52.7	54.2	
standard deviation	± 24.1	± 25.6	-
Age of onset of atopic dermatitis (AD)			
Measure Analysis Population Description: Number of subjects analysed = subjects with available data for the baseline parameter.			
Units: Years			

median	3.0	3.0	
inter-quartile range (Q1-Q3)	1.0 to 14.0	0.0 to 13.0	-
Duration of atopic dermatitis			
Measure Analysis Population Description: Number of subjects analysed = subjects with available data for the baseline parameter.			
Units: Years			
arithmetic mean	27.9	29.6	
standard deviation	± 14.5	± 15.1	-

End points

End points reporting groups

Reporting group title	Initial treatment period - Tralokinumab 300 mg Q2W

Reporting group description:

Week 0 to Week 16:

Tralokinumab 300 mg Q2W

Tralokinumab: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for SC administration.

Reporting group title	Initial treatment period - Placebo Q2W

Reporting group description:

Week 0 to Week 16:

Placebo Q2W

Placebo: Placebo contains the same excipients, in the same concentration, only lacking tralokinumab.

Reporting group title	Open-label Treatment: Tralokinumab 300 mg Q2W + optional TCS

Reporting group description:

Week 16 to Week 52:

Subjects receiving initial treatment with tralokinumab/placebo Q2W who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) OR Subjects receiving maintenance treatment with tralokinumab 300 mg Q2W/Q4W or placebo Q2W assigned to open-label treatment after Week 16 with tralokinumab 300 mg Q2W regimen + optional TCS if: -IGA of at least 2 and not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA=0 at Week 16; OR -IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e. over 3 consecutive visits) for subjects with IGA=1 at Week 16; OR -Not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA>1 at Week 16.

Reporting group title	Maintenance Treatment Period - Tralokinumab 300 mg Q2W

Reporting group description:

Week 16 to Week 52: Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to tralokinumab 300 mg Q2W maintenance dosing regimen.

Reporting group title	Maintenance Treatment Period - Tralokinumab 300 mg Q4W

Reporting group description:

Week 16 to Week 52: Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to tralokinumab 300 mg Q4W maintenance dosing regimen.

Reporting group title	Maintenance Treatment Period - Placebo Q2W

Reporting group description:

Week 16 to Week 52: Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to placebo Q2W dosing regimen.

Reporting group title	Maintenance Treatment Period -Placebo Q2W - Tralokinumab Naive

Reporting group description:

Week 16 to Week 52: Subjects achieving a clinical response at Week 16 and initially randomised to placebo re-assigned to placebo Q2W.

Reporting group title	Open-label Treatment - Tralokinumab 300 mg Q2W + Optional TCS

Reporting group description:

Week 52 to Week 66 [Short term extension (Japan only)]:

Japanese subjects who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of

active therapy.

Each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.

Primary: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16

End point title	Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16

End point description:

The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The full analysis set (FAS: all subjects randomised to initial treatment who were exposed to IMP) was used for the primary analysis; 802 subjects were randomised to initial treatment and 798 received IMP, thus the FAS comprised of 798 subjects.

End point type	Primary

End point timeframe:

At Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Number of subjects	95	14		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W versus Placebo

Statistical analysis description:

The analysis was performed using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity. The null hypothesis of no difference in response rates between tralokinumab and placebo were tested against the 2-sided alternative that there is a difference.

Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority[1]
P-value	= 0.002 [2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	8.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.1
upper limit	13.1

Notes:

[1] - Primary endpoints tested sequentially at a 5% significance level.

[2] - Based on primary analysis of primary estimand composite. Subjects with missing data or subjects who received res cue medication prior to Week 16 were considered non-responders. Primary endpoints tested sequentially at a 5% significance level.

Primary: Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16

End point title	Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16

End point description:

The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition. The FAS was used for the primary analysis; 802 subjects were randomised to initial treatment and 798 received IMP, thus the FAS comprised of 798 subjects.

End point type	Primary

End point timeframe:

At Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Number of subjects	150	25		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W versus Placebo

Statistical analysis description:

Analysis was performed using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity. The null hypothesis of no difference in response rates between tralokinumab and placebo were tested against the 2-sided alternative that there is a difference.

Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 [3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	12.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.5
upper limit	17.7

Notes:

[3] - Based on the primary analysis of primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders. Primary endpoints tested sequentially at a 5% significance level.

Secondary: Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16

End point title	Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16

End point description:

SCORAD was used to assess the extent and severity of AD. The maximum total score is 103, with higher values indicating more severe disease. The FAS included all randomised subjects.

End point type	Secondary

End point timeframe:

Week 0 to Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Adjusted mean change				
arithmetic mean (standard error)	-25.2 (± 0.94)	-14.7 (± 1.80)		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W versus Placebo

Statistical analysis description:

Data collected after permanent discontinuation of IMP or initiation of rescue medication not included.

Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority[4]
P-value	< 0.001 [5]
Method	Repeated measurements model
Parameter estimate	Difference
Point estimate	-10.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.4
upper limit	-6.5

Notes:

[4] - Multiplicity adjustment using the Holm method.

[5] - Based on the primary analysis of the primary estimand 'hypothetical'. Repeated measurements model on post-baseline data. In case of no post-baseline assessments before initiation of rescue

medication, the Week 2 change was imputed as 0.

Secondary: Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.

End point title	Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.

End point description:

Subjects assessed their worst itch severity over the past 24 hours using an 11point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.

Number of subjects analysed = subjects with baseline pruritus NRS weekly average ≥4.

End point type	Secondary

End point timeframe:

Week 0 to Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	594	194		
Units: Number of subjects	119	20		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W versus Placebo
Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	788
Analysis specification	Pre-specified
Analysis type	superiority[6]
P-value	= 0.002 [7]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	9.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.4
upper limit	15

Notes:

[6] - Multiplicity adjustment using Holm method.

[7] - Based on the primary analysis of the primary estimand 'Composite', subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders'.

Secondary: Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16

End point title	Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16

End point description:

The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). Maintenance analysis set - Subjects who achieved IGA 0/1 at Week 16 after initial treatment with tralokinumab without use of rescue medication.

End point type	Secondary

End point timeframe:

At Week 52

End point values	Maintenance Treatment Period - Tralokinumab 300 mg Q2W	Maintenance Treatment Period - Tralokinumab 300 mg Q4W	Maintenance Treatment Period - Placebo Q2W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	39	36	19	
Units: Number of subjects	20	14	9	

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W versus Placebo

Statistical analysis description:

Testing according to the hierarchical testing procedure in the order: IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo.

Comparison groups	Maintenance Treatment Period - Tralokinumab 300 mg Q2W v Maintenance Treatment Period - Placebo Q2W
Number of subjects included in analysis	58
Analysis specification	Pre-specified
Analysis type	superiority[10]
P-value	= 0.68 [11]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.8
upper limit	33.7

Notes:

[10] - This test was not statistically significant and hence next maintenance endpoint in the sequential testing procedure was not evaluated.
[11] - Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-labe l treatment were considered non-responders. The P value was considered non-significant.

Statistical analysis title	Tralokinumab 300 mg Q4W versus Placebo
Comparison groups	Maintenance Treatment Period - Placebo Q2W v Maintenance

	Treatment Period - Tralokinumab 300 mg Q4W
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	-9.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.1
upper limit	18

Secondary: Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16

End point title	Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16

End point description:

The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.

End point type	Secondary

End point timeframe:

At Week 52

End point values	Maintenance Treatment Period - Tralokinumab 300 mg Q2W	Maintenance Treatment Period - Tralokinumab 300 mg Q4W	Maintenance Treatment Period - Placebo Q2W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	57	30	
Units: Number of subjects	28	28	10	

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W versus Placebo

Statistical analysis description:

Testing according to the hierarchical testing procedure in the order: IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo.

Comparison groups	Maintenance Treatment Period - Tralokinumab 300 mg Q2W v Maintenance Treatment Period - Placebo Q2W

Number of subjects included in analysis	77
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.056 [12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	21.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	42.6

Notes:

[12] - Test not evaluated for statistical significance. Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-labe l treatment were considered non-responders.

Statistical analysis title	Tralokinumab 300 mg Q4W versus Placebo
Comparison groups	Maintenance Treatment Period - Tralokinumab 300 mg Q4W v Maintenance Treatment Period - Placebo Q2W
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.27 [13]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	11.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.7
upper limit	32

Notes:

[13] - Test not evaluated for statisitical significance. Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-labe l treatment were considered non-responders.

Secondary: Safety and Tolerability: Adverse event (AE) /Serious adverse event (SAE) Frequency

End point title	Safety and Tolerability: Adverse event (AE) /Serious adverse event (SAE) Frequency

End point description:

Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section.

End point type	Secondary

End point timeframe:

Week 0 to Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	602	196		
Units: Number of subjects				
AE	411	133		
SAE	23	8		

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of Anti-drug Antibodies

End point title	Frequency of Anti-drug Antibodies

End point description:

Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method.

End point type	Secondary

End point timeframe:

Week 0 to Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	602	196		
Units: Number of subjects				
Total positive	10	3		
Pre-existing	0	2		
Treatment-boosted	0	0		
Treatment emergent	10	1		
Perishing	5	3		
Negative	564	177		
No post-baseline anti-drug antibody assessment	23	13		

Statistical analyses

No statistical analyses for this end point

Secondary: Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16

End point title	Subjects Achieving at Least 50% Reduction in Eczema Area and

	Severity Index [EASI] at Week 16

End point description:

The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.

End point type	Secondary

End point timeframe:

At Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Number of subjects	250	42		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W

Statistical analysis description:

Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.

Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 [14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	20.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.3
upper limit	26.8

Notes:

[14] - The statistical test was not controlled for multiplicity.

Secondary: Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16

End point title	Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16

End point description:

The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.

End point type	Secondary

End point timeframe:

At Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Number of subjects	87	8		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W
Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 [15]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	10.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.4
upper limit	14.1

Notes:

[15] - Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders. The statistical test was not controlled for multiplicity.

Secondary: Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score

End point title	Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score

End point description:

The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.

End point type	Secondary

End point timeframe:

Week 0 to Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Units on a scale				
least squares mean (confidence interval 95%)	-15.5 (-16.6 to -14.4)	-9.0 (-11.1 to -7.0)		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W
Statistical analysis description:	
Data collected after permanent discontinuation of IMP or initiation of rescue medication not included. In case of no post-baseline assessments before initiation of rescue medication, the Week 2 change will be imputed as 0.	
Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 [16]
Method	Repeated measurements model
Parameter estimate	Difference of least square means
Point estimate	-6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	-4.1

Notes:

[16] - The statistical test was not controlled for multiplicity.

Secondary: Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

End point title	Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16
End point description:	
The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.	
End point type	Secondary
End point timeframe:	
At Week 16	

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Number of subjects	53	6		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W
Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.007 [17]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	5.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.5
upper limit	8.9

Notes:

[17] - Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication prior to Week 16 or with missing data at Week 16 were considered nonresponders. The statistical test was not controlled for multiplicity.

Secondary: Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

End point title	Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

End point description:

The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.

End point type	Secondary

End point timeframe:

At Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	601	197		
Units: Number of subjects	156	23		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W
Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	798
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 [18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	14.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.6
upper limit	19.6

Notes:

[18] - Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication prior to Week 16 or with missing data at Week 16 were considered non-responders. The statistical test was not controlled for multiplicity.

Secondary: Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average)

End point title	Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average)

End point description:

Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'

End point type	Secondary

End point timeframe:

Week 0 to Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	598	195		
Units: Units on a scale				
least squares mean (confidence interval 95%)	-2.6 (-2.8 to -2.4)	-1.7 (-2.1 to -1.3)		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W

Statistical analysis description:

Data collected after permanent discontinuation of IMP or initiation of rescue medication not included. In case of no post-baseline assessments before initiation of rescue medication, the Week 1 change will be imputed as 0.

Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	793
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 [19]
Method	Repeated measurements model
Parameter estimate	Difference of least square means
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	-0.4

Notes:

[19] - The statistical test was not controlled for multiplicity.

Secondary: Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16

End point title	Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16

End point description:

Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'. Number of subjects analysed = subjects with baseline Pruritus NRS weekly average of at least 3.

End point type	Secondary

End point timeframe:

Week 0 to Week 16

End point values	Initial treatment period - Tralokinumab 300 mg Q2W	Initial treatment period - Placebo Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	597	195		
Units: Number of subjects	177	28		

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W
Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	792
Analysis specification	Pre-specified

Statistical analyses

Statistical analysis title	Tralokinumab 300 mg Q2W vs Placebo Q2W
Comparison groups	Initial treatment period - Tralokinumab 300 mg Q2W v Initial treatment period - Placebo Q2W
Number of subjects included in analysis	768
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001 [21]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	13
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.4
upper limit	20.5

Notes:

[21] - Subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders. The statistical test was not controlled for multiplicity.

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
Timeframe for AE	
Adverse event reporting additional description:	
AE additional description	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	20

Reporting groups	
Reporting group title	Initial Period - Tralokinumab Q2W
Reporting group description: -	
Reporting group title	Initial Period - Placebo
Reporting group description: -	
Reporting group title	Maintenance Period - Tralokinumab Q2W
Reporting group description: -	
Reporting group title	Maintenance Period - Tralokinumab Q4W
Reporting group description: -	
Reporting group title	Maintenance Period - Placebo
Reporting group description: -	
Reporting group title	Maintenance Period - Placebo - Tralokinumab Naive
Reporting group description: -	
Reporting group title	Open-label Period - Tralokinumab Q2W + Optional TCS
Reporting group description: -	
Reporting group title	Safety Follow-up
Reporting group description: -	

Serious adverse events	Initial Period - Tralokinumab Q2W	Initial Period - Placebo	Maintenance Period - Tralokinumab Q2W
Total subjects affected by serious adverse events			
subjects affected / exposed	23 / 602 (3.82%)	8 / 196 (4.08%)	1 / 68 (1.47%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive breast carcinoma			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Accelerated hypertension			

subjects affected / exposed	0 / 602 (0.00%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 602 (0.00%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery stenosis			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Granuloma			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site reaction			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Strangulated hernia			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Ovarian cyst ruptured			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 602 (0.17%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 602 (0.00%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin increased			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			

subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Accessory cardiac pathway			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute left ventricular failure			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			

subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive encephalopathy			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Eosinophilia			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Lens dislocation			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Ulcerative keratitis			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver disorder			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	4 / 602 (0.66%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis exfoliative generalised			
subjects affected / exposed	2 / 602 (0.33%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatomyositis			

subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperhidrosis			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stag horn calculus			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 602 (0.00%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polymyalgia rheumatica			
subjects affected / exposed	0 / 602 (0.00%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rotator cuff syndrome			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 602 (0.00%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 602 (0.17%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	1 / 68 (1.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 602 (0.00%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			

subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis bacterial			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis viral			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leishmaniasis			
subjects affected / exposed	1 / 602 (0.17%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			

subjects affected / exposed	0 / 602 (0.00%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Maintenance Period - Tralokinumab Q4W	Maintenance Period - Placebo	Maintenance Period - Placebo - Tralokinumab Naive
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 76 (3.95%)	0 / 35 (0.00%)	1 / 29 (3.45%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive breast carcinoma			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery stenosis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Granuloma			

subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site reaction			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Strangulated hernia			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Ovarian cyst ruptured			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 76 (1.32%)	0 / 35 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			

subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	1 / 76 (1.32%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin increased			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Accessory cardiac pathway			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Acute left ventricular failure			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive encephalopathy			

subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Eosinophilia			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Lens dislocation			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcerative keratitis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			

subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver disorder			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis exfoliative generalised			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatomyositis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperhidrosis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stag horn calculus			

subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	1 / 76 (1.32%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polymyalgia rheumatica			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cystitis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis bacterial			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis viral			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leishmaniasis			

subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 76 (1.32%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Open-label Period - Tralokinumab Q2W + Optional TCS	Safety Follow-up	
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 563 (4.80%)	16 / 595 (2.69%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive breast carcinoma			
subjects affected / exposed	2 / 563 (0.36%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated hypertension			

subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Granuloma			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injection site reaction			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strangulated hernia			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Ovarian cyst ruptured			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Troponin increased			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			

subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Accessory cardiac pathway			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute left ventricular failure			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	3 / 563 (0.53%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure acute			

subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ataxia			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Eosinophilia			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Lens dislocation			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Ulcerative keratitis			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	2 / 563 (0.36%)	3 / 595 (0.50%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis exfoliative generalised			
subjects affected / exposed	0 / 563 (0.00%)	2 / 595 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatomyositis			

subjects affected / exposed

Rotator cuff syndrome			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	2 / 563 (0.36%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Furuncle			

subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratitis bacterial			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratitis viral			
subjects affected / exposed	0 / 563 (0.00%)	1 / 595 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leishmaniasis			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 563 (0.00%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			

subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Initial Period - Tralokinumab Q2W	Initial Period - Placebo	Maintenance Period - Tralokinumab Q2W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	351 / 602 (58.31%)	114 / 196 (58.16%)	37 / 68 (54.41%)
Investigations			
Liver function test increased			
subjects affected / exposed	4 / 602 (0.66%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences (all)	4	0	0
Injury, poisoning and procedural complications			
Wrong patient received medication			
subjects affected / exposed	8 / 602 (1.33%)	1 / 196 (0.51%)	0 / 68 (0.00%)
occurrences (all)	13	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	28 / 602 (4.65%)	10 / 196 (5.10%)	6 / 68 (8.82%)
occurrences (all)	50	16	12
General disorders and administration site conditions			
Injection site reaction			
subjects affected / exposed	24 / 602 (3.99%)	0 / 196 (0.00%)	5 / 68 (7.35%)
occurrences (all)	47	0	13
Eye disorders			
Conjunctivitis allergic			
subjects affected / exposed	16 / 602 (2.66%)	3 / 196 (1.53%)	3 / 68 (4.41%)
occurrences (all)	16	4	3
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	10 / 602 (1.66%)	1 / 196 (0.51%)	4 / 68 (5.88%)
occurrences (all)	11	1	4
Oropharyngeal pain			

subjects affected / exposed	10 / 602 (1.66%)	1 / 196 (0.51%)	1 / 68 (1.47%)
occurrences (all)	11	1	1
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	152 / 602 (25.25%)	75 / 196 (38.27%)	11 / 68 (16.18%)
occurrences (all)	198	123	14
Pruritus			
subjects affected / exposed	32 / 602 (5.32%)	10 / 196 (5.10%)	2 / 68 (2.94%)
occurrences (all)	41	15	2
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	5 / 602 (0.83%)	2 / 196 (1.02%)	3 / 68 (4.41%)
occurrences (all)	5	2	3
Tendonitis			
subjects affected / exposed	3 / 602 (0.50%)	0 / 196 (0.00%)	0 / 68 (0.00%)
occurrences (all)	3	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	11 / 602 (1.83%)	4 / 196 (2.04%)	3 / 68 (4.41%)
occurrences (all)	12	4	3
Conjunctivitis			
subjects affected / exposed	43 / 602 (7.14%)	4 / 196 (2.04%)	3 / 68 (4.41%)
occurrences (all)	50	4	3
Influenza			
subjects affected / exposed	18 / 602 (2.99%)	5 / 196 (2.55%)	4 / 68 (5.88%)
occurrences (all)	18	5	5
Nasopharyngitis			
subjects affected / exposed	15 / 602 (2.49%)	2 / 196 (1.02%)	0 / 68 (0.00%)
occurrences (all)	16	2	0
Viral upper respiratory tract infection			
subjects affected / exposed	139 / 602 (23.09%)	41 / 196 (20.92%)	14 / 68 (20.59%)
occurrences (all)	172	54	17

Non-serious adverse events	Maintenance Period - Tralokinumab Q4W	Maintenance Period - Placebo	Maintenance Period - Placebo - Tralokinumab Naive
Total subjects affected by non-serious adverse events			
subjects affected / exposed	39 / 76 (51.32%)	20 / 35 (57.14%)	9 / 29 (31.03%)

Investigations			
Liver function test increased			
subjects affected / exposed	0 / 76 (0.00%)	2 / 35 (5.71%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
Injury, poisoning and procedural complications			
Wrong patient received medication			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 76 (2.63%)	3 / 35 (8.57%)	0 / 29 (0.00%)
occurrences (all)	2	6	0
General disorders and administration site conditions			
Injection site reaction			
subjects affected / exposed	7 / 76 (9.21%)	1 / 35 (2.86%)	0 / 29 (0.00%)
occurrences (all)	21	1	0
Eye disorders			
Conjunctivitis allergic			
subjects affected / exposed	1 / 76 (1.32%)	2 / 35 (5.71%)	0 / 29 (0.00%)
occurrences (all)	1	2	0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 76 (0.00%)	2 / 35 (5.71%)	0 / 29 (0.00%)
occurrences (all)	0	2	0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	14 / 76 (18.42%)	13 / 35 (37.14%)	6 / 29 (20.69%)
occurrences (all)	22	18	10
Pruritus			
subjects affected / exposed	4 / 76 (5.26%)	1 / 35 (2.86%)	2 / 29 (6.90%)
occurrences (all)	5	1	2
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	4 / 76 (5.26%)	0 / 35 (0.00%)	1 / 29 (3.45%)
occurrences (all)	4	0	1
Tendonitis			
subjects affected / exposed	0 / 76 (0.00%)	0 / 35 (0.00%)	2 / 29 (6.90%)
occurrences (all)	0	0	2
Infections and infestations			
Bronchitis			
subjects affected / exposed	7 / 76 (9.21%)	2 / 35 (5.71%)	1 / 29 (3.45%)
occurrences (all)	8	2	1
Conjunctivitis			
subjects affected / exposed	4 / 76 (5.26%)	0 / 35 (0.00%)	0 / 29 (0.00%)
occurrences (all)	6	0	0
Influenza			
subjects affected / exposed	3 / 76 (3.95%)	1 / 35 (2.86%)	0 / 29 (0.00%)
occurrences (all)	3	1	0
Nasopharyngitis			
subjects affected / exposed	3 / 76 (3.95%)	2 / 35 (5.71%)	0 / 29 (0.00%)
occurrences (all)	3	2	0
Viral upper respiratory tract infection			
subjects affected / exposed	18 / 76 (23.68%)	4 / 35 (11.43%)	2 / 29 (6.90%)
occurrences (all)	26	5	4

Non-serious adverse events	Open-label Period - Tralokinumab Q2W + Optional TCS	Safety Follow-up	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	304 / 563 (54.00%)	29 / 595 (4.87%)	
Investigations			
Liver function test increased			
subjects affected / exposed	1 / 563 (0.18%)	0 / 595 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
Wrong patient received medication			
subjects affected / exposed	2 / 563 (0.36%)	0 / 595 (0.00%)	
occurrences (all)	2	0	
Nervous system disorders			

Headache			
subjects affected / exposed	22 / 563 (3.91%)	1 / 595 (0.17%)	
occurrences (all)	29	1	
General disorders and administration site conditions			
Injection site reaction			
subjects affected / exposed	28 / 563 (4.97%)	0 / 595 (0.00%)	
occurrences (all)	60	0	
Eye disorders			
Conjunctivitis allergic			
subjects affected / exposed	13 / 563 (2.31%)	2 / 595 (0.34%)	
occurrences (all)	14	2	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	5 / 563 (0.89%)	1 / 595 (0.17%)	
occurrences (all)	5	1	
Oropharyngeal pain			
subjects affected / exposed	10 / 563 (1.78%)	0 / 595 (0.00%)	
occurrences (all)	10	0	
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	123 / 563 (21.85%)	10 / 595 (1.68%)	
occurrences (all)	201	12	
Pruritus			
subjects affected / exposed	20 / 563 (3.55%)	0 / 595 (0.00%)	
occurrences (all)	27	0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	18 / 563 (3.20%)	0 / 595 (0.00%)	
occurrences (all)	19	0	
Tendonitis			
subjects affected / exposed	6 / 563 (1.07%)	0 / 595 (0.00%)	
occurrences (all)	6	0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	14 / 563 (2.49%)	1 / 595 (0.17%)	
occurrences (all)	15	1	

Conjunctivitis			
subjects affected / exposed	41 / 563 (7.28%)	4 / 595 (0.67%)	
occurrences (all)	52	4	
Influenza			
subjects affected / exposed	7 / 563 (1.24%)	2 / 595 (0.34%)	
occurrences (all)	7	2	
Nasopharyngitis			
subjects affected / exposed	5 / 563 (0.89%)	1 / 595 (0.17%)	
occurrences (all)	5	1	
Viral upper respiratory tract infection			
subjects affected / exposed	143 / 563 (25.40%)	12 / 595 (2.02%)	
occurrences (all)	201	12	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 August 2017	The reason for the amendment was due to a request for changes from the Health Authorities in Europe after their review of the protocol. The main amendments are listed below. 1) It was clarified that all subjects in the trial will have a safety follow-up visit (end of trial visit) 16 weeks after last injection of IMP (investigational medicinal product), including those that are offered participation in the long-term extension trial conducted under a separate protocol (LP0162 1337). This was to ensure that safety follow-up information was collected for all subjects enrolled in this trial, and to ensure that a safety evaluation could be made based on data collected after IMP had been discontinued. Furthermore, the evaluation of anti-drug antibodies was considered to be most reliable when samples are taken in the absence of IMP. 2) 2 additional blood samples (PK and anti drug antibodies) were added at Week 4 to better monitor potential development of immunogenicity. 3) The transfer criteria to open-label treatment was changed to keep subjects who entered maintenance treatment with IGA 0/1 in maintenance treatment until they have a sustained 2 step change in IGA (IGA of 0 becoming ≥2; IGA of 1 becoming ≥3). 4) The exclusion criteria regarding receipt of any marketed (i.e. immunoglobulin, anti-IgE) or investigational biologic agent was updated with dupilumab since it was then approved in USA. 5) Infusion reactions were deleted from the risk list since they are not relevant for this trial. Malignancies and interference with reproductive function were added to align with the Investigator's Brochure. 6) It was clarified that subjects who permanently discontinue IMP prior to Week 16 should also be assessed at the nominal Week 16 visit. This was to allow sensitivity analyses of primary endpoints and secondary endpoints in the initial treatment period. 7) The procedure for emergency unblinding of the individual subject's treatment was clarified.
12 December 2017	The reason for the amendment is due to a request for changes from the Health Authorities in the US after their review of the protocol. The main amendments are listed below. 1) Several 'other endpoints' were included to the trial objectives and endpoints to allow for an evaluation of the efficacy of tralokinumab over time on severity and extent of AD, itch, and health-related quality of life compared with placebo. Additional endpoints were included to evaluate the patient-reported outcomes and health care resource utilisation. 2) Clarification that transfer to open-label requires a persistent worsening of disease observed over 3 consecutive visits in the maintenance period was included. 3) Clarification of how Worst Daily Pruritus NRS at baseline will be calculated was included. 4) Clarification that female subjects of childbearing potential must have used a highly effective form of birth control for at least 1 month prior to baseline was included. 5) Clarification that the small biomarker panel may include more than 7 biomarkers. 6) Clarification that AE reporting starts at screening, not baseline was included. 7) For all randomised subjects the reasons for permanent discontinuation of IMP and for leaving the trial will be presented.

14 August 2018	The main reason for the amendment was that a new anti-drug antibody (ADA) assay had been developed with improved tralokinumab tolerance. It meant that the presence or absence of anti-drug antibodies (ADA) could be determined in serum samples with tralokinumab present. Previously, this was not possible and therefore ADA sampling at the end of the 14-week off-treatment safety follow-up was originally required for the ADA evaluation. Thus, the new ADA assay would allow eligible subjects who have completed the treatment periods of trial LP0162 1325 to continue into the long-term extension trial (conducted under a separate protocol [LP0162 1337, ECZTEND]) without completing the safety follow-up period in the present trial. These subjects would have their safety follow-up period after end-of-treatment in the long-term extension trial.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported